Investigation of Cerebral Motor Activity Modulations Following Median Nerve Stimulation During General Anaesthesia
- Conditions
- Accidental Awareness During General Anesthesia
- Interventions
- Registration Number
- NCT05272202
- Lead Sponsor
- Brugmann University Hospital
- Brief Summary
Accidental Awareness during General Anesthesia (AAGA) occurs in 1-2% of high-risk practice patients and is a cause of severe psychological trauma, termed post-traumatic stress disorder (PTSD). Actually, no monitoring techniques can accurately predict or detect an AAGA. Since the first reflex for a patient during an AAGA is to move, a brain-computer interface (BCI) based on the detection of an intention of movement would be conceivable to alert the anesthetist. The investigators previously showed that median nerve stimulation (MNS) could be the keystone of a BCI specialized in the detection of movement intention. Indeed, based on these previous results, the investigators can envisage a routine system where the patient would be stimulated at the median nerve position, while a BCI device would analyze the event-related desynchronization (ERD) and event-related synchronization (ERS) modulations in the motor cortex to check whether the patient is intending to move or not. According to the investigator's knowledge, no published studies have investigated the detection of EEG patterns in relation to peripheral nerve stimulation over the sensorimotor cortex during general anesthesia. The main objective of this study is to describe the changes in terms of ERD and ERS modulations, in the EEG signal over the motor cortex, during general anesthesia with propofol, while a median nerve stimulation is performed.
STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. Changes in ERD and ERS during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. Pre- and post-injection comparisons of propofol will be performed by paired series tests. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 30
- Patients >18 years and <81 years
- Right-handed
- Programmed for surgery with the use of an intravenous anesthesia with a propofol concentration objective
- Allergy to propofol, soy or peanuts
- BMI<20 or >30
- Pregnant or breastfeeding women
- Adult unable to give consent
- Medical or surgical history that may interfere with median nerve stimulation or the obtention of the EEG signal (for example: diabetes, polyneuropathy, central neurodegenerative disease, epilepsy, brain surgery)
- History of right median nerve injury
- Amputation of the upper right limb
- Impossibility of affixing an EEG helmet
- Addiction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Median nerve stimulation EEG measurements - Median nerve stimulation Median nerve stimulation - Median nerve stimulation Propofol -
- Primary Outcome Measures
Name Time Method Amplitude of the ERD (event-related desynchronization)/ERS (event- related synchronization) From the time each stimulation is performed until 4 seconds after the stimulation is completed. The main evaluation outcome will be the amplitude of the ERD (event-related desynchronization)/ERS (event- related synchronization) after median nerve stimulation, within 4 s of the stimulation, at various propofol concentrations. This amplitude will be calculated using a baseline taken before each stimulation. The amplitudes of the ERD and ERS will be extracted. The ERDs and ERSs will be displayed from the time each stimulation is performed until 4 s after the stimulation is completed.
- Secondary Outcome Measures
Name Time Method Detection of ERD patterns via new machine-learning algorithms (percent of correct detection) From the time each stimulation is performed until 4 seconds after the stimulation is completed. Verify the detection of ERD patterns via new machine-learning algorithms at different propofol concentrations. ERD patterns will be analysed manually, as well as automated by a machine-learning algorythm. Endpoint will be the percentage (%) of correctly identified ERD pattern by the algorythm.
Modulation of ERD patterns by anesthetics drugs. Percentage of variation in amplitude. From the time each stimulation is performed until 4 seconds after the stimulation is completed. Another secondary criteria will to describe how the ERD generated by an MNS would be modulated by anesthetics drugs. Amplitude of ERD patterns will be recorded (microV) and the effect of anesthetic drugs on this amplitude will be described as percentage change.
Detection of ERS patterns via new machine-learning algorithms (percentage of correct detection) From the time each stimulation is performed until 4 seconds after the stimulation is completed. Verify the detection of ERS patterns via new machine-learning algorithms at different propofol concentrations. ERS patterns will be analysed manually, as well as automated by a machine-learning algorythm. Endpoint will be the percentage (%) of correctly identified ERS pattern by the algorythm.
Modulation of ERS patterns by anesthetics drugs via new machine-learning algorithms (percentage change in amplitude) From the time each stimulation is performed until 4 seconds after the stimulation is completed. Another secondary criteria will to describe how the ERS generated by an MNS would be modulated by anesthetics drugs. Amplitude of ERS patterns will be recorded (microV) and the effect of anesthetic drugs on this amplitude will be described as percentage change.
Trial Locations
- Locations (1)
CHU Brugmann
🇧🇪Brussels, Belgium